MORGAN STANLEY PLC/CALL/GILEAD SCIENCES/115/0.1/20.06.25

MORGAN STANLEY PLC/CALL/GILEAD SCIENCES/115/0.1/20.06.25 Stock

DE000ME08NH3

Real-time Bid/Ask 09:24:54 2024-06-07 am EDT
0.046 ^EUR / 0.061 ^EUR	+10.20%

Current month	+36.11%
1 month	+13.95%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart GILEAD SCIENCES, INC.

Chart MORGAN STANLEY PLC/CALL/GILEAD SCIENCES/115/0.1/20.06.25

Latest news about GILEAD SCIENCES, INC.

Combination therapy may hold potential for severe viral hepatitis	Jun. 06	AQ
Gilead's Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis	Jun. 06	AQ
Gilead Says Bulevirtide With PegIFN Data 'Superior' to Bulevirtide Monotherapy; Achieves 46% Rate of Undetectable HDV RNA	Jun. 06	MT
Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA	Jun. 06	BU

More news

Quotes 5-day view

Date	Price	Change
24-06-07	0.047	-4.08%
24-06-06	0.049	-2.00%
24-06-05	0.05	0.00%
24-06-04	0.05	+42.86%
24-06-03	0.035	-2.78%

Delayed Quote Börse Stuttgart

Last update June 07, 2024 at 08:14 am EDT

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	GILEAD SCIENCES, INC.
Issuer	Morgan Stanley
WKN	ME08NH
ISIN	DE000ME08NH3
Date issued	2023-09-01
Strike	115 $
Maturity	2025-06-20 (378 Days)
Parity	10 : 1
Emission price	0.19 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	0.33 €
Lowest since issue	0.032 €
Spread	0.013 €
Spread %	21.67%

Company Profile

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Sector

More about the company

Ratings for Gilead Sciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Consensus: Gilead Sciences, Inc.

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

63.85 USD

Average target price

82.7 USD

Spread / Average Target

+29.52%

Consensus